numbness, tingling, burning pain, or weakness in hands or feet
12; 95% CI, 1
32 with rifabutin as the companion rifamycin), and for rifabutin-containing regimens than rifampin-containing regimens
Intermittent regiment: 10 to 20 mg IV or orally 2 to 3 times a week
33% of reviewers reported a positive effect, while 67% reported a negative
Therapeutic drug monitoring (TDM), that is, individualized drug dosing guided by drug plasma concentrations, could be of help in improving the patient response to drug treatment
257 major drug
Mycobacterium avium complex (MAC) is the most common cause of lung disease caused by non-tuberculous mycobacteria in many countries